vs
MESA LABORATORIES INC（MLAB）与Perimeter Solutions, Inc.（PRM）财务数据对比。点击上方公司名可切换其他公司
Perimeter Solutions, Inc.的季度营收约是MESA LABORATORIES INC的1.6倍（$102.8M vs $65.1M），MESA LABORATORIES INC净利率更高（5.6% vs -136.5%，领先142.1%），Perimeter Solutions, Inc.同比增速更快（19.2% vs 3.6%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $11.6M），过去两年Perimeter Solutions, Inc.的营收复合增速更高（31.9% vs 5.1%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
Perimeter Solutions是一家以色列云与网络安全企业，专为各类机构打造基于零信任架构的安全远程网络方案，其技术可替代VPN、防火墙等传统安全硬件设备，助力企业简化网络安全部署，提升远程访问的安全性与效率。
MLAB vs PRM — 直观对比
营收规模更大
PRM
是对方的1.6倍
$65.1M
营收增速更快
PRM
高出15.5%
3.6%
净利率更高
MLAB
高出142.1%
-136.5%
自由现金流更多
MLAB
多$6.4M
$11.6M
两年增速更快
PRM
近两年复合增速
5.1%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $102.8M |
| 净利润 | $3.6M | $-140.2M |
| 毛利率 | 64.2% | 45.2% |
| 营业利润率 | 12.2% | -160.7% |
| 净利率 | 5.6% | -136.5% |
| 营收同比 | 3.6% | 19.2% |
| 净利润同比 | 316.6% | -197.3% |
| 每股收益（稀释后） | $0.65 | $-0.89 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABPRM
| Q4 25 | $65.1M | $102.8M | ||
| Q3 25 | $60.7M | $315.4M | ||
| Q2 25 | $59.5M | $162.6M | ||
| Q1 25 | $62.1M | $72.0M | ||
| Q4 24 | $62.8M | $86.2M | ||
| Q3 24 | $57.8M | $288.4M | ||
| Q2 24 | $58.2M | $127.3M | ||
| Q1 24 | $58.9M | $59.0M |
净利润MLABPRM
| Q4 25 | $3.6M | $-140.2M | ||
| Q3 25 | $2.5M | $-90.7M | ||
| Q2 25 | $4.7M | $-32.2M | ||
| Q1 25 | $-7.1M | $56.7M | ||
| Q4 24 | $-1.7M | $144.2M | ||
| Q3 24 | $3.4M | $-89.2M | ||
| Q2 24 | $3.4M | $21.6M | ||
| Q1 24 | $-254.6M | $-82.6M |
毛利率MLABPRM
| Q4 25 | 64.2% | 45.2% | ||
| Q3 25 | 61.5% | 63.1% | ||
| Q2 25 | 62.0% | 62.4% | ||
| Q1 25 | 61.8% | 39.1% | ||
| Q4 24 | 63.3% | 48.6% | ||
| Q3 24 | 61.3% | 62.8% | ||
| Q2 24 | 64.0% | 57.6% | ||
| Q1 24 | 62.1% | 35.1% |
营业利润率MLABPRM
| Q4 25 | 12.2% | -160.7% | ||
| Q3 25 | 7.8% | -27.7% | ||
| Q2 25 | 5.1% | -16.1% | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 9.2% | 71.1% | ||
| Q3 24 | 6.1% | -12.2% | ||
| Q2 24 | 9.6% | 35.4% | ||
| Q1 24 | -460.6% | -126.8% |
净利率MLABPRM
| Q4 25 | 5.6% | -136.5% | ||
| Q3 25 | 4.1% | -28.7% | ||
| Q2 25 | 8.0% | -19.8% | ||
| Q1 25 | -11.4% | 78.7% | ||
| Q4 24 | -2.7% | 167.2% | ||
| Q3 24 | 5.9% | -30.9% | ||
| Q2 24 | 5.8% | 17.0% | ||
| Q1 24 | -432.2% | -139.8% |
每股收益（稀释后）MLABPRM
| Q4 25 | $0.65 | $-0.89 | ||
| Q3 25 | $0.45 | $-0.62 | ||
| Q2 25 | $0.85 | $-0.22 | ||
| Q1 25 | $-1.30 | $0.36 | ||
| Q4 24 | $-0.31 | $1.00 | ||
| Q3 24 | $0.63 | $-0.61 | ||
| Q2 24 | $0.62 | $0.14 | ||
| Q1 24 | $-47.26 | $-0.57 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | $325.9M |
| 总债务越低越好 | $68.4M | $669.1M |
| 股东权益账面价值 | $186.7M | $1.1B |
| 总资产 | $434.8M | $2.7B |
| 负债/权益比越低杠杆越低 | 0.37× | 0.59× |
8季度趋势，按日历期对齐
现金及短期投资MLABPRM
| Q4 25 | $29.0M | $325.9M | ||
| Q3 25 | $20.4M | $340.6M | ||
| Q2 25 | $21.3M | $140.7M | ||
| Q1 25 | $27.3M | $200.1M | ||
| Q4 24 | $27.3M | $198.5M | ||
| Q3 24 | $24.3M | $223.1M | ||
| Q2 24 | $28.5M | $43.2M | ||
| Q1 24 | $28.2M | $38.7M |
总债务MLABPRM
| Q4 25 | $68.4M | $669.1M | ||
| Q3 25 | $69.4M | $668.8M | ||
| Q2 25 | $70.3M | $668.4M | ||
| Q1 25 | $71.3M | $668.1M | ||
| Q4 24 | $72.2M | $667.8M | ||
| Q3 24 | $73.1M | $667.4M | ||
| Q2 24 | $74.1M | $667.1M | ||
| Q1 24 | — | $666.8M |
股东权益MLABPRM
| Q4 25 | $186.7M | $1.1B | ||
| Q3 25 | $178.5M | $1.1B | ||
| Q2 25 | $172.5M | $1.2B | ||
| Q1 25 | $159.8M | $1.2B | ||
| Q4 24 | $155.2M | $1.2B | ||
| Q3 24 | $161.5M | $1.0B | ||
| Q2 24 | $150.7M | $1.1B | ||
| Q1 24 | $145.4M | $1.1B |
总资产MLABPRM
| Q4 25 | $434.8M | $2.7B | ||
| Q3 25 | $430.4M | $2.6B | ||
| Q2 25 | $435.7M | $2.5B | ||
| Q1 25 | $433.3M | $2.4B | ||
| Q4 24 | $433.3M | $2.4B | ||
| Q3 24 | $454.1M | $2.5B | ||
| Q2 24 | $440.4M | $2.3B | ||
| Q1 24 | $446.8M | $2.3B |
负债/权益比MLABPRM
| Q4 25 | 0.37× | 0.59× | ||
| Q3 25 | 0.39× | 0.60× | ||
| Q2 25 | 0.41× | 0.57× | ||
| Q1 25 | 0.45× | 0.55× | ||
| Q4 24 | 0.47× | 0.58× | ||
| Q3 24 | 0.45× | 0.67× | ||
| Q2 24 | 0.49× | 0.62× | ||
| Q1 24 | — | 0.63× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | $18.6M |
| 自由现金流经营现金流 - 资本支出 | $18.0M | $11.6M |
| 自由现金流率自由现金流/营收 | 27.7% | 11.3% |
| 资本支出强度资本支出/营收 | 1.1% | 6.8% |
| 现金转化率经营现金流/净利润 | 5.17× | — |
| 过去12个月自由现金流最近4个季度 | $37.9M | $208.6M |
8季度趋势，按日历期对齐
经营现金流MLABPRM
| Q4 25 | $18.8M | $18.6M | ||
| Q3 25 | $8.2M | $198.7M | ||
| Q2 25 | $1.9M | $-2.9M | ||
| Q1 25 | $12.7M | $23.7M | ||
| Q4 24 | $18.1M | $-6.0M | ||
| Q3 24 | $5.3M | $183.0M | ||
| Q2 24 | $10.7M | $8.6M | ||
| Q1 24 | $12.9M | $2.8M |
自由现金流MLABPRM
| Q4 25 | $18.0M | $11.6M | ||
| Q3 25 | $7.1M | $193.6M | ||
| Q2 25 | $884.0K | $-15.6M | ||
| Q1 25 | $11.9M | $18.9M | ||
| Q4 24 | $17.3M | $-12.4M | ||
| Q3 24 | $3.5M | $179.1M | ||
| Q2 24 | $9.9M | $5.0M | ||
| Q1 24 | $12.3M | $1.2M |
自由现金流率MLABPRM
| Q4 25 | 27.7% | 11.3% | ||
| Q3 25 | 11.7% | 61.4% | ||
| Q2 25 | 1.5% | -9.6% | ||
| Q1 25 | 19.2% | 26.3% | ||
| Q4 24 | 27.6% | -14.4% | ||
| Q3 24 | 6.0% | 62.1% | ||
| Q2 24 | 16.9% | 3.9% | ||
| Q1 24 | 21.0% | 2.1% |
资本支出强度MLABPRM
| Q4 25 | 1.1% | 6.8% | ||
| Q3 25 | 1.8% | 1.6% | ||
| Q2 25 | 1.7% | 7.8% | ||
| Q1 25 | 1.2% | 6.7% | ||
| Q4 24 | 1.3% | 7.5% | ||
| Q3 24 | 3.1% | 1.3% | ||
| Q2 24 | 1.5% | 2.9% | ||
| Q1 24 | 0.9% | 2.6% |
现金转化率MLABPRM
| Q4 25 | 5.17× | — | ||
| Q3 25 | 3.32× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | — | 0.42× | ||
| Q4 24 | — | -0.04× | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 3.17× | 0.40× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
PRM
| Products | $87.7M | 85% |
| Service And Other | $14.8M | 14% |
